14029.93.
(a) Commencing January 1, 2020, all Medi-Cal beneficiary materials translated into threshold languages and released by the department, and informing materials as defined in subdivision (e) that are translated into threshold languages and released by managed care plans contracting with the department, shall be field tested as part of the translation process, except as described in subdivisions (c) and (d).(b) (1) For purposes of this section, “field testing” means a review of translations for accuracy, cultural appropriateness, and
readability.
(2) Field testing shall be conducted by a focus group, or another form of review, involving native speakers of the applicable language or community-based organizations with an understanding of the linguistic needs of the targeted population.
(3) Field testing may be administered internally by the department or the managed care plan, or by a third-party contractor, including, but not limited to, an entity already contracted for translation.
(c) Information contained in a material on an individualized, nonstandard basis for a Medi-Cal beneficiary, including, but not limited to, personal identifying information or specific information regarding a Medi-Cal beneficiary’s medical condition, shall
not be field tested.
(d) Information released to Medi-Cal beneficiaries during a state of emergency or a local emergency, as defined in Section 8558 of the Government Code, that cannot be written before the state of emergency or local emergency, including information required pursuant to Section 1368.7 of the Health and Safety Code or Section 8594.16 of the Government Code, is exempt from the field testing requirement described in this section.
(e) For purposes of this section, “informing materials” means documents that provide Medi-Cal managed care members with essential information about access to, and usage of, plan services, including only the following:
(1) Plan termination notices.
(2) New member welcome packets.
(3) Member handbooks.
(4) Forms and information regarding grievance or complaint procedures and information regarding external review of plan decisions.
(5) Forms and information regarding appeals and adverse benefit determinations.
(f) For purposes of this section, “managed care plan” refers to any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:
(1) Article 2.7 (commencing with Section
14087.3).
(2) Article 2.8 (commencing with Section 14087.5).
(3) Article 2.81 (commencing with Section 14087.96).
(4) Article 2.82 (commencing with Section 14087.98).
(5) Article 2.91 (commencing with Section 14089).
(6) Chapter 8 (commencing with Section 14200).
(7) Chapter 8.9 (commencing with Section 14700).
(8) A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration, Number 11-W-00193/9, as approved by the federal Centers for Medicare
and Medicaid Services and described in the Special Terms and Conditions. For purposes of this paragraph, “Special Terms and Conditions” has the same meaning as set forth in subdivision (o) of Section 14184.10.